Skip to main content

Table 2 Best response according to RECIST in both groups

From: Customized chemotherapy based on epidermal growth factor receptormutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial

  Gefitinib (N = 22) VNR or GEM (N = 32)
Complete response 0 0
Partial response 10 (45.5%) 6 (18.8%)
Stable disease 9 (40.9%) 12 (37.5%)
Progressive disease 1 (4.5%) 6 (18.8%)
Not evaluable 2 (9.1%) 8 (25.0%)
  1. GEM: gemcitabine; RECIST: Response Evaluation Criteria in Solid Tumors; VNR: vinorelbine.